Motilium (Domperidone)

Domperidone, the active ingredient in Motilium, is a dopamine D2 receptor antagonist presented as an oral tablet for oral use. It is employed to alleviate nausea, vomiting, and to improve gastrointestinal motility in adults and functional dyspepsia symptoms in appropriate patients under medical supervision.

GNH USA supplies Motilium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures consistent quality and regulatory compliance across all markets, enabling reliable access for healthcare providers through validated supply chain processes and timely delivery.

Domperidone acts on the gastrointestinal tract and the chemoreceptor trigger zone to control nausea and improve motility. - Nausea: reduces episodes of nausea associated with various causes, including chemotherapy and postoperative states. - Vomiting: decreases the frequency and intensity of vomiting in acute and chronic settings. - Gastroparesis: enhances gastric emptying and relieves symptoms of delayed stomach emptying. - Functional dyspepsia: alleviates upper abdominal discomfort and early satiety. - Gastroesophageal reflux: reduces reflux episodes by improving lower esophageal sphincter tone.

Domperidone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry mouth: reduced salivation leading to throat discomfort. - Headache: mild to moderate intensity. - Abdominal cramps: intermittent stomach pain. - Dizziness: sensation of light‑headedness. - Constipation: decreased bowel movements. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including QT prolongation. - Extrapyramidal symptoms: muscle rigidity or tremor. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hyperprolactinemia: elevated prolactin causing galactorrhoea. - Galactorrhoea: unexpected milk secretion. - Liver enzyme elevation: signs of hepatic stress.

Before prescribing domperidone, clinicians should consider several safety precautions to minimize risk. - Assess cardiac risk: evaluate QT interval and avoid use in patients with known arrhythmias. - Review concomitant medications: avoid combination with other QT‑prolonging agents. - Monitor hepatic function: adjust use in patients with liver impairment. - Caution in electrolyte imbalance: correct potassium or magnesium disturbances before treatment. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Domperidone interacts with several drug classes, requiring attention to avoid adverse effects or reduced efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase domperidone plasma levels. - Other QT‑prolonging drugs (e.g., quinidine, sotalol): additive risk of cardiac arrhythmia. - Antifungal agents (e.g., itraconazole): may elevate domperidone concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may lower domperidone effectiveness. - Anticholinergic agents: combined anticholinergic burden may affect gastrointestinal motility. - Other antiemetics (e.g., metoclopramide): overlapping mechanisms may increase side‑effect risk.